DE68906077T2 - Interleukin-1-inhibitoren. - Google Patents

Interleukin-1-inhibitoren.

Info

Publication number
DE68906077T2
DE68906077T2 DE8989109540T DE68906077T DE68906077T2 DE 68906077 T2 DE68906077 T2 DE 68906077T2 DE 8989109540 T DE8989109540 T DE 8989109540T DE 68906077 T DE68906077 T DE 68906077T DE 68906077 T2 DE68906077 T2 DE 68906077T2
Authority
DE
Germany
Prior art keywords
interleukin
inhibitor
inhibitors
recombinant
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8989109540T
Other languages
English (en)
Other versions
DE68906077D1 (de
Inventor
Charles H Hannum
Stephen P Eisenberg
Robert C Thompson
William P Arend
Fenneke G Joslin
Andreas Sommer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Boulder Inc
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergen Inc filed Critical Synergen Inc
Publication of DE68906077D1 publication Critical patent/DE68906077D1/de
Application granted granted Critical
Publication of DE68906077T2 publication Critical patent/DE68906077T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/545IL-1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/30Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8989109540T 1988-05-27 1989-05-26 Interleukin-1-inhibitoren. Expired - Lifetime DE68906077T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19991588A 1988-05-27 1988-05-27
US23871388A 1988-08-31 1988-08-31
US24852188A 1988-09-23 1988-09-23
US26653188A 1988-11-03 1988-11-03

Publications (2)

Publication Number Publication Date
DE68906077D1 DE68906077D1 (de) 1993-05-27
DE68906077T2 true DE68906077T2 (de) 1993-07-29

Family

ID=27498356

Family Applications (4)

Application Number Title Priority Date Filing Date
DE68929387T Expired - Lifetime DE68929387T2 (de) 1988-05-27 1989-05-26 Interleukin-1-Inhibitoren
DE198989109540T Pending DE343684T1 (de) 1988-05-27 1989-05-26 Interleukin-1-inhibitoren.
DE8989109540T Expired - Lifetime DE68906077T2 (de) 1988-05-27 1989-05-26 Interleukin-1-inhibitoren.
DE2002199011 Active DE10299011I2 (de) 1988-05-27 1989-05-26 Interleukin-1-Inhibitoren.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE68929387T Expired - Lifetime DE68929387T2 (de) 1988-05-27 1989-05-26 Interleukin-1-Inhibitoren
DE198989109540T Pending DE343684T1 (de) 1988-05-27 1989-05-26 Interleukin-1-inhibitoren.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE2002199011 Active DE10299011I2 (de) 1988-05-27 1989-05-26 Interleukin-1-Inhibitoren.

Country Status (14)

Country Link
EP (3) EP0541920B1 (de)
KR (1) KR0148009B1 (de)
AT (2) ATE88502T1 (de)
CA (1) CA1341322C (de)
DE (4) DE68929387T2 (de)
ES (2) ES2176181T3 (de)
GR (1) GR900300115T1 (de)
HK (2) HK1017821A1 (de)
IE (1) IE66712B1 (de)
IL (1) IL90423A (de)
LU (1) LU90943I2 (de)
NL (1) NL300091I2 (de)
NZ (1) NZ229326A (de)
SG (1) SG59969A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
EP0502956B1 (de) * 1989-11-29 1997-04-23 Amgen Boulder Inc. Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
DE69131044T2 (de) * 1990-05-01 1999-11-18 Chiron Corp Interleukin-i antagonist und seine verwendung
EP0639079B1 (de) * 1992-04-30 2000-01-12 Amgen Inc. Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
HUP9900169A2 (hu) * 1995-09-13 2000-03-28 Takeda Chemical Industries, Ltd. Immunoszuppresszáns hatású kinolin- vagy kinozalinszármazékok és ezeket tartalmazó gyógyászati készítmények
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU7103198A (en) * 1997-04-21 1998-11-13 Schering Corporation Mammalian cytokines; related reagents and methods
US7205381B2 (en) 1997-04-21 2007-04-17 Schering Corporation Mammalian cytokines; related reagents and methods
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
EP1068321A2 (de) 1998-04-03 2001-01-17 Hyseq, Inc. Ein interleukin-1 rezeptor antagonist und seine verwendungen
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6680380B1 (en) 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
AU6296899A (en) * 1998-10-08 2000-04-26 Zymogenetics Inc. Interleukin-1 homolog
WO2001042305A1 (en) * 1999-12-10 2001-06-14 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
ES2395953T3 (es) 2005-01-26 2013-02-18 Amgen Fremont Inc. Anticuerpos frente a interleucina-1 beta
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
JP5894364B2 (ja) 2007-08-16 2016-03-30 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼および付属器組織の炎症を処置するための治療組成物
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
CN107337735B (zh) 2010-07-29 2021-06-22 巴扎德制药公司 嵌合il-1受体i型激动剂和拮抗剂
WO2012076193A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
WO2012076194A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit cytokin-antagonist und corticosteroid
BR112015022587A2 (pt) 2013-03-13 2017-10-24 Eleven Biotherapeutics Inc formulações de citocina quimérica para entrega ocular
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0138654B1 (ko) * 1987-08-26 1998-04-30 프레드릭 에이. 유스티스, 3세 인터루킨-i 저해제 및 이의 제조방법

Also Published As

Publication number Publication date
DE68929387D1 (de) 2002-05-16
KR0148009B1 (ko) 1998-08-01
EP0343684B1 (de) 1993-04-21
EP1133995A3 (de) 2001-09-26
SG59969A1 (en) 1999-02-22
IE66712B1 (en) 1996-01-24
NL300091I1 (nl) 2002-07-01
EP0343684A1 (de) 1989-11-29
HK1017821A1 (en) 1999-11-26
ATE88502T1 (de) 1993-05-15
HK1039901A1 (zh) 2002-05-17
GR900300115T1 (en) 1991-09-27
KR900700618A (ko) 1990-08-16
IE950317L (en) 1989-11-27
CA1341322C (en) 2001-11-27
NL300091I2 (nl) 2002-08-01
ES2176181T3 (es) 2002-12-01
ATE215966T1 (de) 2002-04-15
EP1133995A2 (de) 2001-09-19
DE68906077D1 (de) 1993-05-27
ES2018750A4 (es) 1991-05-16
DE10299011I2 (de) 2006-03-16
EP0541920A1 (de) 1993-05-19
DE68929387T2 (de) 2002-08-14
IL90423A (en) 2000-07-26
IL90423A0 (en) 1990-01-18
DE10299011I1 (de) 2002-07-18
IE891781L (en) 1989-11-27
LU90943I2 (fr) 2002-09-30
NZ229326A (en) 1992-12-23
DE343684T1 (de) 1990-11-08
EP0541920B1 (de) 2002-04-10
ES2018750T3 (es) 1994-10-16

Similar Documents

Publication Publication Date Title
DE68906077T2 (de) Interleukin-1-inhibitoren.
IT8721618A0 (it) Prodecimento per la depurazione bilogica di acque reflue.
DE69030582D1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
IT8521037A0 (it) Procedimento per la polimerizzazione di isoprene.
IT1189589B (it) Procedimento per l'esercizio di un estrusore
NO894499L (no) Fremgangsmaate for separering av folinsyre.
IT8921162A0 (it) Procedimento per la fabbricazione di pezzi stampati ceramici.
IT8721560A0 (it) Procedimento per la purificazione di interferone.
ES2165358T3 (es) Utilizaciones de la proteinquinasa de neurofilamento/tau pk40.
IT8520090A0 (it) Procedimento di purificazione di un enzima.
IT8722452A0 (it) Processo per la sintesi di una n ndialchil idrossilammina.
ES510546A0 (es) "procedimiento de preparar derivados de n-(n-metil-rn(n-aminosulfenil disubstituido)carbamoil)oxi)tioacetamidato de s-metilo".
DE3881538D1 (de) Verwendung eines klebstoffes zur palettisierung.
DE209855T1 (de) Aminosaeure-derivate, nuetzlich zur deaktivation von enzymen.
DE3674575D1 (de) Verwendung von optisch-aktiven carboalkylierten aminoalkohole zur trennung von optischen isomeren.
IT1231506B (it) Procedimento per la purificazione di polieteri polioli.
IT8620828A0 (it) Procedimento per la produzione di una l-aspartil-l-fenilalanina n-protetta.
SE8501412L (sv) Teltenhet
IT8819389A0 (it) Procedimento per depurazione di acque di scarico industriale.
IT8821083A0 (it) Procedimento per la realizzazione di fogli autoadesivi.
IT8820665A0 (it) Procedimento per la preparazione di (s) e (r) alfa, beta isopropilidenglicerolo.
ITRM940151A0 (it) Impiego di esteruretani per la riconcia.
IT8720114A0 (it) Procedimento migliorato per la purificazione di l-carnitinato di l-carnitina.
ITTO910025A0 (it) Procedimento ed impianto per la depurazione di fanghi biologici